.jpg)
STAT+: A very good day for Lilly, and a bad day for Novo
The biotech stories you need to read, brought to you by The Readout.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today we talk about Eli Lilly’s stock jumping after it released new data on its GLP-1 pill, see Sanofi partner with a mysterious company, and more.
A very good day for Lilly, and a bad day for Novo
From my colleague Elaine Chen: Eli Lilly’s stock shot up 14% yesterday, after the pharma giant reported the first Phase 3 results of its GLP-1 pill orforglipron. The small molecule helped patients with type 2 diabetes improve their blood sugar levels and shed weight, results that were nearly comparable to the benefits of available injectable GLP-1 drugs.
